Welcome to our dedicated page for Selecta Biosciences news (Ticker: SELB), a resource for investors and traders seeking the latest updates and insights on Selecta Biosciences stock.
Selecta Biosciences, Inc. (symbol: SELB) is a clinical-stage biopharmaceutical company dedicated to enhancing the efficacy of biologic therapies by reducing unwanted immune responses. The company's innovative approach leverages its proprietary tolerogenic Synthetic Vaccine Particles (SVP™) technology, which is designed to enable a wide range of biologics, particularly for rare and serious diseases that lack effective treatment options.
Selecta's current pipeline features SVP-enabled enzyme, oncology, and gene therapies. Leading the pipeline is SEL-212, a promising candidate in Phase 2 trials targeting severe gout. SEL-212 aims to alleviate debilitating symptoms such as flares and gouty arthritis, offering much-needed relief to patients. Another noteworthy candidate is SEL-403, a combination therapy comprising SVP-Rapamycin and LMB-100, which entered Phase 1 trials in 2018 for treating malignant pleural or peritoneal mesothelioma.
In addition to enzyme and oncology therapies, Selecta is developing gene therapy product candidates designed for rare metabolic disorders. These candidates hold the potential to enable repeat dosing and long-term efficacy. The company’s research endeavors are backed by a series of collaborations and partnerships that bolster its scientific and commercial capabilities.
The company's latest news highlights significant progress in its clinical trials and partnerships. Notable developments include updates on the potential of its Descartes-08 and Descartes-15 therapies to treat myasthenia gravis and other autoimmune diseases, as well as advancements in RNA Armory® technology.
Selecta continues to focus on mitigating risks inherent in clinical trials, regulatory processes, and funding requirements. The company's strategic initiatives and forward-looking statements are guided by its commitment to addressing unmet medical needs and bringing innovative therapies to market.
On August 5, 2021, Selecta Biosciences, Inc. (NASDAQ: SELB) announced a conference call scheduled for August 12, 2021, at 8:30 a.m. ET. The call will discuss financial results for Q2 2021, which ended on June 30, 2021, along with a business update. Selecta utilizes its ImmTOR™ platform to develop immunology therapies aimed at mitigating unwanted immune responses. The company has several proprietary and partnered programs focused on various therapies, including gene and enzyme therapies, indicating diverse growth avenues.
On August 2, 2021, Selecta Biosciences, a biotechnology company focused on immunotherapies, announced CEO Carsten Brunn's participation in two upcoming investor conferences. The conferences are the BTIG Virtual Biotechnology Conference on August 9, 2021, at 3:00 p.m. EDT, and the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 9:30 a.m. EDT. Selecta Biosciences leverages its ImmTOR™ platform to develop therapies that mitigate unwanted immune responses, with several proprietary and partnered programs in its pipeline.
Selecta Biosciences (NASDAQ: SELB) has appointed gene therapy expert Jude Samulski, Ph.D., as a special advisor to enhance its gene therapy initiatives. This follows the publication of pre-clinical data indicating that ImmTOR nanoparticles significantly improve transgene expression in a mouse model of methylmalonic acidemia. The findings suggest ImmTOR's capacity to mitigate the immune response against AAV vectors, enabling potential re-dosing and improved patient treatment outcomes. The company anticipates filing an IND for its lead candidate, MMA-101, by year-end 2021.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced participation in the William Blair Biotech Focus Conference 2021, taking place virtually on July 14-15. CEO Carsten Brunn, Ph.D., will hold one-on-one investor meetings, while CSO Takashi Kei Kishimoto, Ph.D., will join a panel discussion titled Delivery and Durability of Genetic Medicines on July 15 at 10:00 a.m. ET. Selecta focuses on developing tolerogenic therapies through its ImmTOR™ platform, aimed at reducing unwanted immune responses and enhancing the effectiveness of biologic treatments.
On June 24, 2021, Selecta Biosciences, Inc. (NASDAQ: SELB) announced the appointment of Dr. Nishan de Silva to its Board of Directors. With over 20 years of experience in biotechnology, he will provide valuable strategic guidance as Selecta advances its clinical pipeline. Dr. de Silva's background includes leadership roles in gene therapy development and operations at companies like Poseida Therapeutics and AFYX Therapeutics. His expertise is expected to enhance Selecta's capabilities in developing safer and more effective gene therapies for serious diseases.
On June 16, 2021, Selecta Biosciences (NASDAQ: SELB) announced that CEO Carsten Brunn, Ph.D., will provide a corporate update and engage in one-on-one investor meetings at the Raymond James Human Health Innovation Conference, scheduled for June 21-23, 2021. The presentation will take place on June 23 at 12:00 p.m. ET, available via the conference portal. Selecta leverages its ImmTOR™ platform to develop therapies that mitigate unwanted immune responses, targeting autoimmune diseases, enzyme, and gene therapies. More information can be found on Selecta's official website.
Selecta Biosciences, Inc. (NASDAQ: SELB) announced that its CEO, Carsten Brunn, Ph.D., will present a corporate update at the LifeSci Partners Genetic Medicines Summit 2021 on June 22 at 9:30 a.m. ET. This event will highlight Selecta's ImmTOR™ platform, which develops tolerogenic therapies to mitigate unwanted immune responses. To register for the presentation, a link is provided. An archived webcast will also be available on the company's website, detailing Selecta's clinical-stage advancements in gene and enzyme therapies.
On June 1, 2021, Selecta Biosciences (NASDAQ: SELB) announced the publication of a study demonstrating that its ImmTOR nanoparticles enhance the tolerogenic environment in the liver, which is crucial for treating autoimmune diseases like primary biliary cholangitis (PBC). The peer-reviewed study reveals that ImmTOR induces a tolerogenic phenotype in liver antigen-presenting cells, potentially protecting against autoimmune hepatitis. The company is advancing its ImmTOR platform in clinical development for PBC, aiming to restore immune tolerance in affected patients.
Selecta Biosciences (NASDAQ: SELB) announced that its CEO, Carsten Brunn, Ph.D., will present a corporate update at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The presentation is scheduled for June 1 at 9:30 a.m. ET and will be accessible via the Jefferies conference portal. Selecta's ImmTOR™ platform is designed to develop therapies that address unwanted immune responses, with programs targeting rare metabolic disorders and autoimmune diseases, along with ongoing collaborations in clinical trials.
Selecta Biosciences reported its first quarter 2021 financial results, showing a revenue recognition of $11.1 million from a license agreement with Sobi. Cash and equivalents rose to $149.2 million, sufficient to sustain operations into mid-2023. The company anticipates topline data from SEL-212's DISSOLVE study in late 2022, and IND filings for various gene therapy and enzyme programs by year-end 2021. However, a net loss of $24.6 million was noted for the quarter, reflecting ongoing R&D investments.
FAQ
What is the market cap of Selecta Biosciences (SELB)?
What does Selecta Biosciences, Inc. specialize in?
What is SEL-212?
What is the significance of SVP™ technology?
What are the current projects in Selecta's pipeline?
What recent achievements has Selecta Biosciences made?
What partnerships does Selecta Biosciences have?
What is SEL-403?
How does Selecta Biosciences address risks in clinical trials?
What are the potential applications of Selecta's gene therapy candidates?
What are the key developments in Selecta's latest news?
